Policy Developments - The National Health Commission and five other departments released measures to enhance the experience of family doctor contract services, focusing on improving service quality and health management for residents [2] Drug and Device Approvals - Novo Nordisk's Wegovy (semaglutide 2.4mg) received FDA approval for treating metabolic-associated fatty liver disease (MASH) with moderate to severe liver fibrosis, which is expected to boost sales [3] - Yiling Pharmaceutical's new traditional Chinese medicine, "Children's Lianhua Qinggan Granules," has received acceptance for its new drug registration application [4] - Pumen Technology obtained a medical device registration certificate for its high-sensitivity cardiac troponin I testing kit, which aids in diagnosing myocardial infarction [5] Financial Reports - Ping An Good Doctor reported a 19.5% increase in revenue to approximately 2.502 billion yuan and a net profit increase of 136.8% to 134 million yuan for the first half of the year [6] - Weier Pharmaceutical's revenue decreased by 2.1% to 674 million yuan, with a net profit decline of 7.77% to 72.77 million yuan in the same period [7] Capital Market Activities - Jianzhijia plans to sell its Qinhuangdao logistics center assets for approximately 24 million yuan, which does not constitute a related party transaction [8] - Gilead Sciences announced a placement of 52.4 million shares at a discount of about 9.9%, with expected net proceeds of approximately 467.69 million HKD, primarily for clinical trials related to obesity [9] Industry News - The National Disease Control Bureau reported a decline in new cases of Chikungunya fever in Foshan, with daily cases dropping from over 600 to below 100, indicating effective control measures [10] - A breakthrough study from Harvard University demonstrated the ability to induce human pluripotent stem cells to initiate meiosis, offering new hope for addressing infertility [11] Public Sentiment Alerts - Baiotai announced that Xinyu Qiheng reduced its stake by 0.78%, selling 3.2169 million shares and raising approximately 105 million yuan [12]

Core Viewpoint - Weir Pharmaceuticals (603351.SH) reported its semi-annual results for 2025, highlighting the current institutional investor holdings and changes in share ownership [1] Institutional Holdings - As of August 19, 2025, three institutional investors disclosed holding a total of 18.5823 million shares of Weir Pharmaceuticals, representing 13.72% of the company's total share capital [1] - The institutional holding percentage decreased by 0.66 percentage points compared to the previous quarter [1] Public Fund Holdings - Three public funds were disclosed this period, including Huaxia CSI 500 Index Enhanced A, Dongxing Lianzhong One-Year Holding Period Mixed A, and Dongxing Pharmaceutical Biotechnology Quantitative Stock Selection Mixed A [1] Social Security Fund Holdings - One new social security fund disclosed holding Weir Pharmaceuticals, namely Guotai Fund Management Co., Ltd. - Social Security Fund 2103 Portfolio [1] - One previously undisclosed social security fund, the National Social Security Fund 112 Portfolio, was also noted [1]

（文章来源：每日经济新闻） 威尔药业（SH 603351，收盘价：32.28元）8月19日晚间发布半年度业绩报告称，2025年上半年营业收 入约6.74亿元，同比减少2.1%；归属于上市公司股东的净利润约7277万元，同比减少7.77%；基本每股 收益0.54元，同比减少6.9%。 ...

Core Viewpoint - The announcement provides an overview of Nanjing Well Pharmaceutical Group Co., Ltd.'s 2025 semi-annual report, emphasizing the company's commitment to transparency and accuracy in its financial disclosures [4][6]. Company Overview - Nanjing Well Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and sales of pharmaceutical excipients and synthetic lubricating base oil products [4]. Financial Data - The semi-annual report includes key operational data, although specific figures for production, sales, and revenue are not detailed in the provided text [4]. - The report indicates that there were no significant changes in the company's operational situation during the reporting period [4]. Important Events - The company will hold a semi-annual performance briefing on August 28, 2025, to discuss its financial results and operational performance with investors [8][10]. - Investors can submit questions for the briefing from August 21 to August 27, 2025, through the Shanghai Stock Exchange Roadshow Center [9][10].

证券代码：603351 证券简称：威尔药业 公告编号：2025-023 南京威尔药业集团股份有限公司 关于2025年半年度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 二、 主要产品和原材料的价格变动情况 （一）主要产品销售价格变动情况 单位：元/吨（不含税） | 主要产品 | 2025 年 | 1-6 | 月 | 2024 年 | 1-6 | 月 | 变动比例 | | --- | --- | --- | --- | --- | --- | --- | --- | | | 平均售价 | | | 平均售价 | | | | | 主要产品 | 年 月 2025 1-6 平均售价 | 2024 | 年 月 1-6 平均售价 | 变动比例 | | --- | --- | --- | --- | --- | | 1、合成润滑基础油 | 14,953.22 | | 15,992.14 | -6.50% | | 其中：机械类 | 16,415.59 | | 18,069.94 | -9.16% | | 非机械类 | ...

南京威尔药业集团股份有限公司 关于召开 2025 半年度业绩说明会的公告 证券代码：603351 证券简称：威尔药业 公告编号：2025-024 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2025 年 08 月 21 日至 08 月 27 日 16:00 前登录上证路演中心 网站首页点击"提问预征集"栏目或通过公司邮箱 wellyy@wellnj.com 进行提 问。公司将在说明会上对投资者普遍关注的问题进行回答。 一、说明会类型 南京威尔药业集团股份有限公司（以下简称"公司"）已于 2025 年 8 月 20 日发布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司经营 成果、财务状况，公司拟召开 2025 半年度网上业绩说明会，针对 2025 半年度的 经营成果及财务指标的具体情况与投资者进行互动交流与沟通，在信息披露允许 的范围内就投资者关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议召开时间：2025 年 08 月 28 日 09:00-10:00 （二）会 ...

南京威尔药业集团股份有限公司 2025 年半年度报告 公司代码：603351 公司简称：威尔药业 南京威尔药业集团股份有限公司 2025 年半年度报告 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人吴仁荣、主管会计工作负责人唐群松及会计机构负责人（会计主管人员）杨轶 声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 二〇二五年八月 中国 南京 1 / 152 南京威尔药业集团股份有限公司 2025 年半年度报告 重要提示 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告涉及的未来计划、发展战略等前瞻性陈述，不构成公司对投资者的实质承诺，敬请投 资者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性 ...

Core Viewpoint - 威尔药业 reported a decline in both revenue and net profit for the first half of 2025, indicating challenges in the market and competitive pressures [1] Financial Performance - The company achieved a revenue of 674 million yuan, a year-on-year decrease of 2.1% [1] - The net profit attributable to shareholders was 72.77 million yuan, down 7.77% year-on-year [1] Product Performance - Sales volume of pharmaceutical excipients increased by 8.42% year-on-year, while sales revenue decreased by 5.97% [1] - The company focused on its advantageous products, with some excipients and raw materials seeing increased sales in the domestic market [1] Market Conditions - The domestic market is experiencing intensified competition, prompting the company to implement targeted marketing strategies [1] - The demand for traditional Chinese medicine injections has decreased year-on-year, leading to a reduction in sales of related injectable excipients [1] Supply Chain Impact - The influence of centralized drug procurement on drug prices is affecting upstream suppliers, including the company, which plays a crucial role in the supply chain [1] - The pricing of excipients is being impacted as a result of these market dynamics [1]

威尔药业(603351.SH)发布2025年半年度报告，报告期内，公司实现营业收入6.74亿元，同比下降 2.10%。实现归属于上市公司股东的净利润7276.69万元，同比下降7.77%。实现归属于上市公司股东的 扣除非经常性损益的净利润7224.89万元，同比增长4.12%。基本每股收益0.54元。 ...

Group 1 - The core viewpoint of the article highlights that Weir Pharmaceutical (603351) reported a decline in both revenue and net profit for the first half of 2025 [1] - The company achieved operating revenue of 674 million yuan, representing a year-on-year decrease of 2.1% [1] - The net profit attributable to shareholders was 72.77 million yuan, down 7.77% compared to the previous year [1] - Basic earnings per share were reported at 0.54 yuan [1] Group 2 - During the reporting period, the sales volume of synthetic lubricating base oil increased by 3.18% year-on-year [1] - However, the sales revenue from synthetic lubricating base oil experienced a decline of 3.52% [1]